Pharmacophore hybridisation and nanoscale assembly to discover self-delivering lysosomotropic new-chemical entities for cancer therapy
Open Access
- 15 September 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Communications
- Vol. 11 (1), 1-12
- https://doi.org/10.1038/s41467-020-18399-4
Abstract
Integration of the unique advantages of the fields of drug discovery and drug delivery is invaluable for the advancement of drug development. Here we propose a self-delivering one-component new-chemical-entity nanomedicine (ONN) strategy to improve cancer therapy through incorporation of the self-assembly principle into drug design. A lysosomotropic detergent (MSDH) and an autophagy inhibitor (Lys05) are hybridised to develop bisaminoquinoline derivatives that can intrinsically form nanoassemblies. The selected BAQ12 and BAQ13 ONNs are highly effective in inducing lysosomal disruption, lysosomal dysfunction and autophagy blockade and exhibit 30-fold higher antiproliferative activity than hydroxychloroquine used in clinical trials. These single-drug nanoparticles demonstrate excellent pharmacokinetic and toxicological profiles and dramatic antitumour efficacy in vivo. In addition, they are able to encapsulate and deliver additional drugs to tumour sites and are thus promising agents for autophagy inhibition-based combination therapy. Given their transdisciplinary advantages, these BAQ ONNs have enormous potential to improve cancer therapy.Keywords
Funding Information
- China Postdoctoral Science Foundation (International Postdoctoral Exchange Program)
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA199668, R01CA232845)
- U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD086195)
- U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (1R01DE029237)
- UC Davis Comprehensive Cancer Center Support Grant (CCSG) awarded by the National Cancer Institute
This publication has 46 references indexed in Scilit:
- Cytoplasmic STAT3 Represses Autophagy by Inhibiting PKR ActivityMolecular Cell, 2012
- Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiencyProceedings of the National Academy of Sciences of the United States of America, 2012
- Autophagy-regulating small molecules and their therapeutic applicationsChemical Society Reviews, 2012
- Lysosomes and lysosomal cathepsins in cell deathBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2012
- Autophagy and cancer – issues we need to digestJournal of Cell Science, 2012
- Principles of early drug discoveryBritish Journal of Pharmacology, 2011
- Understanding biophysicochemical interactions at the nano–bio interfaceNature Materials, 2009
- Exploiting the enhanced permeability and retention effect for tumor targetingDrug Discovery Today, 2006
- Design and development of polymers for gene deliveryNature Reviews Drug Discovery, 2005
- Challenges for medicinal chemistryDrug Discovery Today, 1996